Patents by Inventor Isobel Maciver
Isobel Maciver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7576194Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: March 7, 2008Date of Patent: August 18, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 7569683Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: March 7, 2008Date of Patent: August 4, 2009Assignees: Board of Regents, The University of Texas System, Wyeth Holding CorporationInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Publication number: 20090137788Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: ApplicationFiled: March 7, 2008Publication date: May 28, 2009Inventors: ERIC J. HANSEN, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Publication number: 20090118486Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: ApplicationFiled: March 7, 2008Publication date: May 7, 2009Inventors: ERIC J. HANSEN, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 7344724Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: June 21, 2004Date of Patent: March 18, 2008Assignees: Board of Regents, The University of Texas System, Wyeth Holdings CorporationInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 7288646Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (ie. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M catarrhalis are disclosed.Type: GrantFiled: June 21, 2004Date of Patent: October 30, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Publication number: 20050137131Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: ApplicationFiled: June 21, 2004Publication date: June 23, 2005Inventors: Eric Hansen, Christoph Aebi, Leslie Cope, Isobel Maciver, Michael Fiske, Ross Fredenburg
-
Publication number: 20050131221Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (ie. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M catarrhalis are disclosed.Type: ApplicationFiled: June 21, 2004Publication date: June 16, 2005Inventors: Eric Hansen, Christoph Aebi, Leslie Cope, Isobel Maciver, Michael Fiske, Ross Fredenburg
-
Patent number: 6753417Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: September 12, 2001Date of Patent: June 22, 2004Assignees: Board of Regents, The University of Texas System, American Cyanamid CompanyInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Publication number: 20030032772Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: ApplicationFiled: September 12, 2001Publication date: February 13, 2003Applicant: The Board of Regents, University of Texas SystemInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 6310190Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: June 21, 1999Date of Patent: October 30, 2001Assignees: Board of Regents, The University of Texas, American CyanamidInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 5993826Abstract: The present disclosure relates to Moraxella catarrhalis outer membrane vesicle (OMV) compositions, to selected antigenic proteins from the outer membranes of M. catarrhalis which have a variety of useful properties, and to monoclonal antibodies against these proteins. Particular "Outer Membrane Proteins" (OMPs) of the invention are characterized as having molecular weights of about 30 kD, 80 kD (also termed CopB protein) and between about 200 and 700 kD (HMWP antigen). Passive immunization with monoclonal antibodies directed against these proteins confers protection against homologous and heterologous Moraxella catarrhalis strains in animal models, and active immunization with outer membrane vesicles also enhances pulmonary clearance of distinct M. catarrhalis strains. This demonstrates both the utility of antibodies in conferring passive immunity and the usefulness of OMPs, or variants thereof, in the preparation of vaccines.Type: GrantFiled: March 2, 1993Date of Patent: November 30, 1999Assignee: Board of Regents, The University of TexasInventors: Eric J. Hansen, Meria E. Helminen, Isobel Maciver
-
Patent number: 5981213Abstract: The present disclosure relates to Moraxella catarrhalis outer membrane vesicle (OMV) compositions, to selected antigenic proteins from the outer membranes of M. catarrhalis which have a variety of useful properties, and to monoclonal antibodies against these proteins. Particular "Outer Membrane Proteins" (OMPs) of the invention are characterized as having molecular weights of about 30 kD, 80 kD (also termed CopB protein) and between about 200 and 700 kD (HMWP antigen). Passive immunization with monoclonal antibodies directed against these proteins confers protection against homologous and heterologous Moraxella catarrhalis strains in animal models, and active immunization with outer membrane vesicles also enhances pulmonary clearance of distinct M. catarrhalis strains. This demonstrates both the utility of antibodies in conferring passive immunity and the usefulness of OMPs, or variants thereof, in the preparation of vaccines.Type: GrantFiled: May 25, 1995Date of Patent: November 9, 1999Assignee: Board of Regents, The University of Texas SystemInventors: Eric J. Hansen, Merja E. Helminen, Isobel Maciver
-
Patent number: 5759813Abstract: The present disclosure relates to selected antigenic proteins obtained from the outer membranes of Moraxella catarrhalis, that are found to have a variety of useful properties. These proteins, termed OMPs ("Outer Membrane Proteins"), are characterized as having molecular weights of about 30 kD, 80 kD and between about 200 and 700 kD, respectively. Studies set forth herein demonstrated that monoclonal antibodies directed against these proteins confer a protective effect against infection by Moraxella catarrhalis organisms in animal models, demonstrating the potential usefulness of such antibodies in conferring passive immunity as well as the potential usefulness of these OMPs, or variants thereof, in the preparation of vaccines. Also disclosed are DNA segments encoding these OMPs, methods for preparing the antigens or variants, through the application of recombinant DNA techniques, as well as diagnostic methods and embodiments.Type: GrantFiled: September 19, 1994Date of Patent: June 2, 1998Assignee: Board of Regents, The University of Texas SystemInventors: Eric J. Hansen, Isobel Maciver, Merja Helminen
-
Patent number: 5599693Abstract: The present disclosure relates to selected antigenic proteins obtained from the outer membranes of Moraxella catarrhalis, that have been found by the inventors to have a variety of useful properties. These proteins, termed OMPs ("Outer Membrane Proteins"), are characterized as having molecular weights of 30, 80 and 100 kD, respectively. Studies set forth herein demonstrate that monoclonal antibodies directed against these proteins confer a protective effect against infection by Moraxella catarrhalis organisms in animal models, demonstrating the potential usefulness of such antibodies in conferring passive immunity as well as the potential usefulness of these OMPs, or variants thereof, in the preparation of vaccines. Also disclosed are DNA segments encoding these OMPs, methods for preparing the antigens, or variants, through the application of recombinant DNA techniques, as well as diagnostic methods and embodiments.Type: GrantFiled: May 25, 1995Date of Patent: February 4, 1997Assignee: American Cyanamid CompanyInventors: Eric J. Hansen, Merja Helminen, Isobel Maciver
-
Patent number: 5552146Abstract: The present disclosure relates to selected antigenic proteins obtained from the outer membranes of Moraxella catarrhalis, that have been found by the inventors to have a variety of useful properties. These proteins, termed OMPs ("Outer Membrane Proteins"), are characterized as having molecular weights of 30, 80 and 100 kD, respectively. Studies set forth herein demonstrate that monoclonal antibodies directed against these proteins confer a protective effect against infection by Moraxella catarrhalis organisms in animal models, demonstrating the potential usefulness of such antibodies in conferring passive immunity as well as the potential usefulness of these OMPs, or variants thereof, in the preparation of vaccines. Also disclosed are DNA segments encoding these OMPs, methods for preparing the antigens, or variants, through the application of recombinant DNA techniques, as well as diagnostic methods and embodiments.Type: GrantFiled: August 15, 1991Date of Patent: September 3, 1996Assignee: Board of Regents, The University of Texas SystemInventors: Eric J. Hansen, Merja Helminen, Isobel Maciver